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Abstract: Matrix assisted laser desorption ionisation mass spectrometry imaging (MALDI-MSI),
was used to obtain images of lipids and metabolite distribution in formalin fixed and embedded in
paraffin (FFPE) whole eye sections containing primary uveal melanomas (UM). Using this technique,
it was possible to obtain images of lysophosphatidylcholine (LPC) type lipid distribution that
highlighted the tumour regions. Laser ablation inductively coupled plasma mass spectrometry
images (LA-ICP-MS) performed on UM sections showed increases in copper within the tumour
periphery and intratumoural zinc in tissue from patients with poor prognosis. These preliminary
data indicate that multi-modal MSI has the potential to provide insights into the role of trace metals
and cancer metastasis.
Keywords: uveal melanoma mass spectrometry imaging; matrix assisted laser desorption ionisation;
laser ablation inductively coupled plasma; cancer progression; genetic biomarkers; heterogeneity
1. Introduction
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults,
particularly amongst the Caucasian population [1]. The majority of patients develop
UM within the choroid region, whilst others develop from the ciliary body or iris. UM
metastases invade distant sites hematogenously, and metastatic spread usually targets the
liver, but can also affect the lungs, skin and bones [2]. Approximately 50% of UM will
metastasize and genetic biomarkers including monsomy 3 (M3) and gain of the long arm of
chromosome 8 (+8q) are highly predictive of a poor outcome [3–5]. Less is however known
about the relationship of genetic changes and the chemical biological information. Tumour
biopsies or surgically removed tumours are routinely formalin fixed and embedded in
paraffin (FFPE) for immediate histological analysis or retained archiving. The FFPE protocol
has been extensively used for tissue preservation based on the methylene bridge cross
linking properties [6,7]. Preparing FFPE tissues for mass spectrometry imaging presents
many challenges, some of which include detachment of tissue from the microscope slide,
interference from remaining paraffin wax, delocalisation and loss of target species of
interest. Mass spectrometry imaging offers a powerful insight into the chemical biology
of diseased tissue in the form of multiplexing experimentation where numerous species
can be viewed within a single experiment in contrast to conventional histological staining.
Observation of mass spectrometry profiles and images can provide invaluable links to and
biological insights into whole disease pathways and networks. MALDI-MSI is a powerful
molecular screening tool and can provide a distinctive molecular snapshot of diseased
tissue. Additionally, these technologies allow conservation of the spatial distribution of a
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target species of interest. One key advantage of LA-ICP-MSI in contrast to MALDI-MSI
is that there is no matrix requirement for sample ionisation which can help to minimise
interference in the observation of images from small molecules. The following preliminary
data reports the use of MALDI-MSI to investigate the retention of small biological molecules
in FFPE whole eye sections containing primary UM. In addition to mapping the spatial
distribution of molecular species that are of potential interest, trace metal analysis was
also performed using LA-ICP-MSI to observe copper and zinc within enucleated eyes to
provide information on the atomic pathology containing primary UM.
2. Results
Following dewaxing and antigen retrieval procedures, FFPE whole eye sections con-
taining primary UM were examined by MALDI-MSI and provided an excellent opportunity
to observe the distributions of species within the different tissues of an organ. Representa-
tive mass spectral images obtained by MALDI-MSI are displayed in Figure 1a–c along with
the corresponding H&E-stained section (Figure 1d). These show the diverse spatial distri-
bution of species throughout the various anatomical regions of the eye (i.e., the choroid,
cornea, retina, lens and UM tumour regions). As can be seen, numerous species within the
small molecule mass range were observable in the MALDI imaging experiments even after
the many wash steps required for FFPE removal, demonstrating it to be a feasible method
to analyse and process different tissues with the same protocol.
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Figure 1. (a–c) Selected MALDI-MSI images of a FFPE section of human eye exhibiting UM with spatial distribution of m/z
586.2, [M + K]+, LPC 20:2 in (c), (d) H&E stained sectioned with (i) cornea, (ii) UM tumour regions, (iii) lens and (iv) optic
nerve regions labelled.
Examples of ion image overlays employing the MALDI imaging technique used within
this preliminary study can be seen in Figure 2.
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MALDI-MS profile data was acquired from the tumour regions of 11 separate sections
of FFPE human eye tissue containing UM over the range m/z 100–1000. The results of
PCA analysis of these data are shown in Figure 3. Sections were from excised eyes from
11 separate patients.
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Clinical pathological details of the 11 patients are given in Table 1. The results of
genetic biomarker analysis for each patient are also reported. Here, initial prognosis was
determined by Fluorescence In Situ Hybridisation (FISH) analysis for copy number changes
of chromosomes 3 and 8 and M3 and 8q+ was indicative of a very poor outcome as reported
previously [8]. For some cases additional information was obtained by aCGH and further
stratified the genetic biomarker classification [9]. There was no clear correlation with
clinical or pathological markers, but patients who were determined as having a very poor
outcome by genetic biomarkers tended to have more variance between readings and less
clustering of data.
Figure 4 shows the LA-ICP-MS data acquired from a section of FFPE human eye
containing UM. Images showing the distribution of Cu, Zn and Fe are given along with
intensity plots for line scans across the tumour.
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Figure 4 shows the LA-ICP-MS data acquired from a section of FFPE human eye con-
taining UM. Images showing the distribution of Cu, Zn and Fe are given along with in-
tensity plots for line scans across the tumour. 
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3.1. Lipid Metabolism in UM Patients
The finding that lipid species can still be observed in FFPE tissue in MALDI-MSI
experiments is encouraging. For example, the LPC peaks (e.g., m/z 586.2, [M + K]+,
LPC 20:2) are observable in these data sets and show some variation between patients. LPC
is hydrolysed to produce lysophospatidic acid (LPA) by lysophospholipase D, otherwise
known as autotaxin [10]. Previous studies of UM have shown that reduced expression
of autotaxin (lysophospholipase D) correlates with a bad prognosis [11]. Thus, higher
levels of LPC could correlate with lower levels of autotaxin expression and hence may
be associated with a poor prognosis. It was also of interest that patients with genetic
biomarkers indicative of a very poor outcome had less clustering of profile technical
replicates, suggesting variation of profile readings (Figure 3). Increasing genetic instability
is considered an enabling characteristic of cancers and is related to progression [12]. It
is possible that those UM identified by genetic biomarkers as being more aggressive
(Table 1), are more progressed, and have greater instability. As such, these UM could
be more heterogeneous, and this may be reflected by the variation of repeat samples for
these cases. Although this data is preliminary, coming from a small patient cohort, the
observations made are scientifically consistent, and provide evidence to suggest that the
species identified are of biological significance and can inform on the metabolic pathways
active in individual UM.
3.2. Elemental Pathology of UM
Analysis of trace metals in other ocular diseases (such as age-related macular de-
generation (AMD)) has included zinc, copper, cadmium, manganese, lead and mercury;
each reported to have a potential role in disease pathogenesis [13–17]. However, there is a
distinct lack of trace elemental research in the UM field. In addition to this, even diseases
like AMD; studies have only observed trace metals within patient serum, plasma and the
vitreous humour making tissue distribution analysis a very exciting prospect in UM [18].
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As can be seen in Figure 4c,d, there appears to be a relative increase in 63Cu towards the
periphery of the tumour in the poor prognosis patient. The link between copper and initia-
tion of angiogenesis is well established through stimulation of proliferation and migration
of endothelial cells, in addition, copper has been shown to impact factors involved in the
initiation of angiogenesis such as VEGF and angiogenin [19–21]. Further to this, previous
work has shown some evidence of the movement of copper to the extracellular space by
endothelial cells and this may provide justification for the increase in peripheral copper
as angiogenesis is being initiated, an important aspect for the growth and metastasis of
tumours [22].
Zinc has been shown to be essential in tumour growth with cell proliferation being
halted in the absence of this element [23,24]. Zinc, however, is required for the activity of
hundreds of enzymes, and its increase in poor prognostic UM could signify high prolifera-
tion/metabolism and justify the apparent increase of intratumoural 66Zn (Figure 4e,f) [25].
Alternatively, both copper and zinc are important in the production of melanin, and as the
poor prognostic UM was more pigmented than the good prognostic UM with lower levels
of zinc, it is possible that these findings are related to the increased levels of melanin [26].
Given that copper is also important to melanogenesis, the findings of its restriction to the
edge of the UM, and unrelated to pigmentation, may therefore be of more interest. Further
investigation is necessary to make any solid link between trace element localisation and
UM patient prognosis, and to ameliorate an atomic pathology pathway for trace elements
and uveal melanoma.
3.3. Linking Tumour Metabolomic Heterogeneity to Clinical and Pathological Details
Solid tumour heterogeneity is well documented within the field of mass spectrom-
etry imaging with advancements made to the visualisation, spectral segmentation and
quantification of key molecular species [27,28]. Complex disease mechanisms continue to
present a challenge when faced with continuous reprogramming of cancer cell metabolism,
especially in rare yet aggressive malignancies like UM. Of interest in these preliminary
imaging and PCA data are potential links between patient clinical and pathological details.
With reference to Table 1 and Figure 3, the patients who were determined as having a very
poor outcome by genetic biomarkers tended to have more variance between readings and
less clustering of data when compared to the groupings and positioning of patients E and J
with good prognosis alone found on the far-right half of the scores plot.
4. Materials and Methods
4.1. Sample Preparation
A series of 11 enucleated eyes containing primary UM were investigated (Ethical
approval STH ref: 15427, REC ref: 09/H1008/141). All patients had been treated over
7 years previously, and 6 UM were determined to have a poor prognosis by assessment
of genetic biomarkers. Genetic biomarkers were determined using a combination of
Fluorescence In Situ Hybridisation (FISH) and array comparative genomic hybridisation
(aCGH) using the methods previously published [8,9]. Of the UM with poor prognosis all
but 1 patient was confirmed as dead. The average survival of all patients was 51 months.
Tissue fixation: The nucleations had been collected within a 6-year time period and
were subject to the same fixation protocol, involving fixation in 10% buffered formalin for
24 h, dehydration in 70% EtOH and paraffin embedded. The 5 µm sections were cut using
a microtome (Leica Microsystems, UK) and mounted onto a histological glass slide. FFPE
tissue sections (n = 15) were stored at room temperature until further analysis.
Tissue preparation: Paraffin was removed from FFPE tissue sections by immersing the
sample twice for 7 min in xylene substitute. The sections were gently hydrated for 4 min
(×2) per solution in 100% EtOH, 95% EtOH and 70% EtOH, consecutively. Tissue was then
submerged in 10 mM ammonium bicarbonate buffer for 5 min (×2). Heat induced antigen
retrieval was then performed by immersing the tissue slide in a sealed tube containing
20 mM Tris-HCl buffer (pH = 9) and gradually brought to 97 ◦C for 45 min using a covered
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water bath. The section was cooled to room temperature, gently rinsed with tap water
(1 min) to remove salt residues and then finally allowed to dry prior to matrix deposition.
The antigen retrieval step, usually crucial for the successful detection of peptides was
retained in the protocol to determine if small molecules still remained detectable by mass
spectrometry within FFPE tissue samples that were prepared for immunohistochemistry
using conventional methodologies.
4.2. MALDI Matrix Deposition
The matrix, CHCA in ethanol/water/TFA (3:1:0.1 by volume), was applied using a
SunCollect pneumatic sprayer (SunChrom, Friedrichsdorf, Germany) (at 5 mg/mL) in a
series of five layers. The first and second layers were sprayed at 3 µL min−1 to allow a
matrix seeding process. Three subsequent layers were sprayed at 3.5 µL min−1 in a fine
spray to ensure sample uniformity.
4.3. Instrumentation
Waters MALDI SYNAPT G2 HDMS–MALDI data were obtained using a Waters
MALDI SYNAPT G2 HDMS mass spectrometer (Waters Corporation, Manchester, UK) to
acquire mass spectra and images. Prior to MALDI-MSI analysis the samples were optically
scanned using a flatbed scanner to produce a digital image for future reference, this image
was then imported into the MALDI HDI software (Waters Corporation) to define the region
to be imaged. The instrument was calibrated prior to analysis using phosphorus red. The
instrument was operated in V-mode and positive ion mode, sensitivity mode (10,000 mass
resolution), all data was acquired in the mass range m/z 100–1000 and the variable repetition
rate Nd:YAG laser was set to 1 kHz. Image acquisitions were performed at 150 × 150 µm
pixel size and 50 × 50 µm pixel size. The data was then converted and visualised using
the High Definition Imaging (HDI) 1.1 software, (Waters Corporation, Manchester, UK);
specificity type—IMS MS; number of most intense peaks—1000; resolution—10,000; low
energy intensity threshold—50 (the low intensity threshold was to allow low abundant
species to be included).
LA-ICP-MSI: Elemental analysis data were acquired using a Perkin Elmer NexION
350X inductively coupled plasma mass spectrometer (PerkinElmer Inc., Shelton, CT, USA)
coupled to a New Wave UP-213 laser ablation chamber with Nd:YAG laser (New Wave
Research, Inc., Fremont, CA, USA). Laser ablation parameters laser energy, spot size
and scan speed were optimised and chosen to secure good spatial resolution without
ablation of the glass slide underneath the section but maximising counts. For whole
enucleated globe imaging, all samples were ablated using a line-by-line scan method,
with laser lines drawn using the New Wave laser ablation kit software leaving 150 µm
between each line. (This left space for another run for reuse of irreplaceable primary
samples.) The quadrupole mass analyser was set to scan for m/z values 13, 56, 63 and
66 and had a scan time of 0.3 s. For tuning of the instrument, this was achieved daily
using a predetermined tuning program provided by the PerkinElmer Syngistix software,
using NIST 612 standard reference material of known trace elements in a glass disc and
PerkinElmer’s own predetermined tuning programme. CPS data was recorded line by
line each having its own comma separated. xl format. The IGOR PRO plugin was used
in the iolite software to separate CPS recordings for each mass of interest and time to
resolve them. A data reduction scheme in the software was used to produce the heat
maps in a time and spatially resolved manner. All these images were normalised using
C13, standard practice for bioimaging soft tissues due to homogenous spread in biological
samples. Initial optimisation of the instrument settings was carried out using resected
tumours and enucleated globe samples and plotting counts per second against time for
individual line scans, at each setting.
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4.4. Haematoxylin and Eosin Staining
Slides from serial sections were immersed in haematoxylin for 1 min, rinsed in tap
water until the water ran clear, immersed in 1% eosin for 30 s and rinsed in tap water until
the water ran clear. They were then dehydrated as follows: 50% ethanol for 2 min, 70%
ethanol for 2 min, 80% ethanol for 2 min, 95% ethanol for 2 min and 4 changes of xylene
applied to each slide for 1 min at a time. Finally, they were mounted with DPX mountant
(Sigma Aldrich, Dorset, UK) and left to dry in the fume hood overnight.
4.5. Statistical Analysis Using MALDI
Principle component analyses (PCA) were performed using MATLAB® (Matrix Labora-
tory) (MathWorks, Inc., Natick, MA, USA) in conjunction with the Eigenvector PLS_Toolbox.
The PCA statistics are representative of the UM data using six technical spectral repeats
per biological sample (n = 11). The technical spectral replicates (six per biological sample)
were acquired manually using MALDI-MS from the tumour regions of each eye section
and MS results were then imported into MATLAB® in.txt format after application of ‘auto-
matic peak detection’ to achieve centroidal peak information using the instrument data
processing software (WatersMassLynxTM Software). Normalisation (2-Norm) and mean
centre were selected and ‘contiguous blocks’ were used for cross-validation.
5. Conclusions
In our study we were able to analyse simultaneously the different tissues of the eye
and make some initial correlations with tumour behaviour and prognosis. Further analysis
on a larger series of UM with more interrogation of the data is required to confirm the
relevance of metabolite variation as determined by MALDI and trace metal analysis using
LA-ICP-MSI.
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